Pharmacogenetics of tardive dyskinesia: an updated review of the literature
Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial muscle movements. Various mechanisms have been proposed for the etiopathophysiology of antipsychotic-induced TD in sc...
Gespeichert in:
| Veröffentlicht in: | Pharmacogenomics 2016-08, Vol.17 (12), p.1339-1351 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1351 |
|---|---|
| container_issue | 12 |
| container_start_page | 1339 |
| container_title | Pharmacogenomics |
| container_volume | 17 |
| creator | Lanning, Rachel K Zai, Clement C Müller, Daniel J |
| description | Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial muscle movements. Various mechanisms have been proposed for the etiopathophysiology of antipsychotic-induced TD in schizophrenia patients with genetic factors playing a prominent role. Earlier association studies have focused on polymorphisms in CYP2D6, dopamine-, serotonin-, GABA- and glutamate genes. This review highlights recent advances in the genetic investigation of TD. Recent promising findings were obtained with the
and
genes. More research, including collection of well-characterized samples, enhancement of genome-wide strategies, gene-gene interaction and epigenetic analyses, is needed before genetic tests with clinical utility can be made available for TD. |
| doi_str_mv | 10.2217/pgs.16.26 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1809604128</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1809604128</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-3b980ba6d3a70322346d491911dd8e5c4ecc464d6b8b7f129f9ee1e2e1cc838b3</originalsourceid><addsrcrecordid>eNpt0MtOxCAUgGFiNN4XvoBp4kYXHeGUodSdmXiLJrrQNaFwqmgvI7Rj5u1FO7owroDkOyfkJ-SA0QkAy0_nz2HCxATEGtlmOeeppBzW450LSIEzsUV2QnilFJjgdJNsQc5FAZncJrcPL9o32nTP2GLvTEi6Kum1t26BiV2GN9dicPos0W0yzK3u0SYeFw4_vuELJrXr0et-8LhHNipdB9xfnbvk6fLicXad3t1f3czO71LDYdqnWVlIWmphM53TDCDjwvKCFYxZK3FqOBrDBbeilGVeMSiqApEhIDNGZrLMdsnxuHfuu_cBQ68aFwzWtW6xG4JikhaCcgYy0qM_9LUbfBt_pyCD2EDIIo_qZFTGdyF4rNTcu0b7pWJUfRVWsbBiQoGI9nC1cSgbtL_yJ2kE0xFUw1eUYBy2BtX4ihPOxKT_LP4Eu_yI6g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2326926897</pqid></control><display><type>article</type><title>Pharmacogenetics of tardive dyskinesia: an updated review of the literature</title><source>MEDLINE</source><source>PubMed Central</source><creator>Lanning, Rachel K ; Zai, Clement C ; Müller, Daniel J</creator><creatorcontrib>Lanning, Rachel K ; Zai, Clement C ; Müller, Daniel J</creatorcontrib><description>Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial muscle movements. Various mechanisms have been proposed for the etiopathophysiology of antipsychotic-induced TD in schizophrenia patients with genetic factors playing a prominent role. Earlier association studies have focused on polymorphisms in CYP2D6, dopamine-, serotonin-, GABA- and glutamate genes. This review highlights recent advances in the genetic investigation of TD. Recent promising findings were obtained with the
and
genes. More research, including collection of well-characterized samples, enhancement of genome-wide strategies, gene-gene interaction and epigenetic analyses, is needed before genetic tests with clinical utility can be made available for TD.</description><identifier>ISSN: 1462-2416</identifier><identifier>EISSN: 1744-8042</identifier><identifier>DOI: 10.2217/pgs.16.26</identifier><identifier>PMID: 27469238</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Antipsychotic Agents - adverse effects ; Antipsychotics ; Brain research ; Brain-derived neurotrophic factor ; CYP2D6 protein ; Cytochrome ; Cytochrome P450 ; Cytokines ; Dopamine ; Enzymes ; Genes ; Genetic analysis ; Genetic factors ; Genetic Predisposition to Disease ; Genetic screening ; genetics ; Genomes ; Humans ; Literature reviews ; Mental disorders ; Meta-analysis ; Metabolism ; Metabolites ; movement disorder ; Movement disorders ; Oxidative stress ; Pharmacogenetics ; Polymorphism ; Psychotropic drugs ; Schizophrenia ; Schizophrenia - complications ; Schizophrenia - drug therapy ; Serotonin ; side effects ; Studies ; Tardive dyskinesia ; Tardive Dyskinesia - epidemiology ; Tardive Dyskinesia - genetics ; γ-Aminobutyric acid</subject><ispartof>Pharmacogenomics, 2016-08, Vol.17 (12), p.1339-1351</ispartof><rights>Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Aug 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-3b980ba6d3a70322346d491911dd8e5c4ecc464d6b8b7f129f9ee1e2e1cc838b3</citedby><cites>FETCH-LOGICAL-c425t-3b980ba6d3a70322346d491911dd8e5c4ecc464d6b8b7f129f9ee1e2e1cc838b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27469238$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanning, Rachel K</creatorcontrib><creatorcontrib>Zai, Clement C</creatorcontrib><creatorcontrib>Müller, Daniel J</creatorcontrib><title>Pharmacogenetics of tardive dyskinesia: an updated review of the literature</title><title>Pharmacogenomics</title><addtitle>Pharmacogenomics</addtitle><description>Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial muscle movements. Various mechanisms have been proposed for the etiopathophysiology of antipsychotic-induced TD in schizophrenia patients with genetic factors playing a prominent role. Earlier association studies have focused on polymorphisms in CYP2D6, dopamine-, serotonin-, GABA- and glutamate genes. This review highlights recent advances in the genetic investigation of TD. Recent promising findings were obtained with the
and
genes. More research, including collection of well-characterized samples, enhancement of genome-wide strategies, gene-gene interaction and epigenetic analyses, is needed before genetic tests with clinical utility can be made available for TD.</description><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotics</subject><subject>Brain research</subject><subject>Brain-derived neurotrophic factor</subject><subject>CYP2D6 protein</subject><subject>Cytochrome</subject><subject>Cytochrome P450</subject><subject>Cytokines</subject><subject>Dopamine</subject><subject>Enzymes</subject><subject>Genes</subject><subject>Genetic analysis</subject><subject>Genetic factors</subject><subject>Genetic Predisposition to Disease</subject><subject>Genetic screening</subject><subject>genetics</subject><subject>Genomes</subject><subject>Humans</subject><subject>Literature reviews</subject><subject>Mental disorders</subject><subject>Meta-analysis</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>movement disorder</subject><subject>Movement disorders</subject><subject>Oxidative stress</subject><subject>Pharmacogenetics</subject><subject>Polymorphism</subject><subject>Psychotropic drugs</subject><subject>Schizophrenia</subject><subject>Schizophrenia - complications</subject><subject>Schizophrenia - drug therapy</subject><subject>Serotonin</subject><subject>side effects</subject><subject>Studies</subject><subject>Tardive dyskinesia</subject><subject>Tardive Dyskinesia - epidemiology</subject><subject>Tardive Dyskinesia - genetics</subject><subject>γ-Aminobutyric acid</subject><issn>1462-2416</issn><issn>1744-8042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpt0MtOxCAUgGFiNN4XvoBp4kYXHeGUodSdmXiLJrrQNaFwqmgvI7Rj5u1FO7owroDkOyfkJ-SA0QkAy0_nz2HCxATEGtlmOeeppBzW450LSIEzsUV2QnilFJjgdJNsQc5FAZncJrcPL9o32nTP2GLvTEi6Kum1t26BiV2GN9dicPos0W0yzK3u0SYeFw4_vuELJrXr0et-8LhHNipdB9xfnbvk6fLicXad3t1f3czO71LDYdqnWVlIWmphM53TDCDjwvKCFYxZK3FqOBrDBbeilGVeMSiqApEhIDNGZrLMdsnxuHfuu_cBQ68aFwzWtW6xG4JikhaCcgYy0qM_9LUbfBt_pyCD2EDIIo_qZFTGdyF4rNTcu0b7pWJUfRVWsbBiQoGI9nC1cSgbtL_yJ2kE0xFUw1eUYBy2BtX4ihPOxKT_LP4Eu_yI6g</recordid><startdate>20160801</startdate><enddate>20160801</enddate><creator>Lanning, Rachel K</creator><creator>Zai, Clement C</creator><creator>Müller, Daniel J</creator><general>Future Medicine Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20160801</creationdate><title>Pharmacogenetics of tardive dyskinesia: an updated review of the literature</title><author>Lanning, Rachel K ; Zai, Clement C ; Müller, Daniel J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-3b980ba6d3a70322346d491911dd8e5c4ecc464d6b8b7f129f9ee1e2e1cc838b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotics</topic><topic>Brain research</topic><topic>Brain-derived neurotrophic factor</topic><topic>CYP2D6 protein</topic><topic>Cytochrome</topic><topic>Cytochrome P450</topic><topic>Cytokines</topic><topic>Dopamine</topic><topic>Enzymes</topic><topic>Genes</topic><topic>Genetic analysis</topic><topic>Genetic factors</topic><topic>Genetic Predisposition to Disease</topic><topic>Genetic screening</topic><topic>genetics</topic><topic>Genomes</topic><topic>Humans</topic><topic>Literature reviews</topic><topic>Mental disorders</topic><topic>Meta-analysis</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>movement disorder</topic><topic>Movement disorders</topic><topic>Oxidative stress</topic><topic>Pharmacogenetics</topic><topic>Polymorphism</topic><topic>Psychotropic drugs</topic><topic>Schizophrenia</topic><topic>Schizophrenia - complications</topic><topic>Schizophrenia - drug therapy</topic><topic>Serotonin</topic><topic>side effects</topic><topic>Studies</topic><topic>Tardive dyskinesia</topic><topic>Tardive Dyskinesia - epidemiology</topic><topic>Tardive Dyskinesia - genetics</topic><topic>γ-Aminobutyric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanning, Rachel K</creatorcontrib><creatorcontrib>Zai, Clement C</creatorcontrib><creatorcontrib>Müller, Daniel J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>UK & Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacogenomics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanning, Rachel K</au><au>Zai, Clement C</au><au>Müller, Daniel J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenetics of tardive dyskinesia: an updated review of the literature</atitle><jtitle>Pharmacogenomics</jtitle><addtitle>Pharmacogenomics</addtitle><date>2016-08-01</date><risdate>2016</risdate><volume>17</volume><issue>12</issue><spage>1339</spage><epage>1351</epage><pages>1339-1351</pages><issn>1462-2416</issn><eissn>1744-8042</eissn><abstract>Tardive dyskinesia (TD) is a serious and potentially irreversible side effect of long-term exposure to antipsychotic medication characterized by involuntary trunk, limb and orofacial muscle movements. Various mechanisms have been proposed for the etiopathophysiology of antipsychotic-induced TD in schizophrenia patients with genetic factors playing a prominent role. Earlier association studies have focused on polymorphisms in CYP2D6, dopamine-, serotonin-, GABA- and glutamate genes. This review highlights recent advances in the genetic investigation of TD. Recent promising findings were obtained with the
and
genes. More research, including collection of well-characterized samples, enhancement of genome-wide strategies, gene-gene interaction and epigenetic analyses, is needed before genetic tests with clinical utility can be made available for TD.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>27469238</pmid><doi>10.2217/pgs.16.26</doi><tpages>13</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1462-2416 |
| ispartof | Pharmacogenomics, 2016-08, Vol.17 (12), p.1339-1351 |
| issn | 1462-2416 1744-8042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1809604128 |
| source | MEDLINE; PubMed Central |
| subjects | Antipsychotic Agents - adverse effects Antipsychotics Brain research Brain-derived neurotrophic factor CYP2D6 protein Cytochrome Cytochrome P450 Cytokines Dopamine Enzymes Genes Genetic analysis Genetic factors Genetic Predisposition to Disease Genetic screening genetics Genomes Humans Literature reviews Mental disorders Meta-analysis Metabolism Metabolites movement disorder Movement disorders Oxidative stress Pharmacogenetics Polymorphism Psychotropic drugs Schizophrenia Schizophrenia - complications Schizophrenia - drug therapy Serotonin side effects Studies Tardive dyskinesia Tardive Dyskinesia - epidemiology Tardive Dyskinesia - genetics γ-Aminobutyric acid |
| title | Pharmacogenetics of tardive dyskinesia: an updated review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T09%3A19%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenetics%20of%20tardive%20dyskinesia:%20an%20updated%20review%20of%20the%20literature&rft.jtitle=Pharmacogenomics&rft.au=Lanning,%20Rachel%20K&rft.date=2016-08-01&rft.volume=17&rft.issue=12&rft.spage=1339&rft.epage=1351&rft.pages=1339-1351&rft.issn=1462-2416&rft.eissn=1744-8042&rft_id=info:doi/10.2217/pgs.16.26&rft_dat=%3Cproquest_cross%3E1809604128%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2326926897&rft_id=info:pmid/27469238&rfr_iscdi=true |